Continuing medical education is available online at www.greenjournal.org
Magnesium Sulfate for Preterm Labor and Preterm Birth Brian M. Mercer, MD, and Amy A. Merlino, MD, for the Society for Maternal-Fetal Medicine Approximately half of the more than 500,000 preterm births each year result from preterm labor. Tocolytic therapy continues to be the focus of treatment of these women. Although a variety of tocolytics are used in clinical practice, magnesium sulfate remains one of the most commonly used agents. Magnesiumsulfate has also been the focus of recent research for its potential neuroprotective effects for neonates born preterm. Evaluation of 19 randomized clinical trials reveals that magnesium sulfate tocolysis does not reduce the frequencies of delivery within 48 hours, 7 days, or early/late preterm birth, and is not associated with improvements in newborn morbidities or mortality. No other tocolytic class resulted in improved newborn outcomes when compared with magnesium sulfate tocolysis. We conclude that it is appropriate to withhold tocolysis with magnesium sulfate or other agents from women presenting in preterm labor as newborn benefit has not been demon- strated with such treatment. If initiated to achieve time for antenatal corticosteroid administration, or for other acute reasons, treatment can be discontinued once these goals have been achieved or if labor subsides before then. Because brief pregnancy prolongation is unlikely to improve newborn outcomes after corticosteroid administration has been completed, it is appropriate to withhold magnesium sulfate tocolysis from women with recurrent preterm labor thereafter. If magnesium sulfate is given for neuroprotection, a protocol from one of the three major trials that have demonstrated benefits should be used. (Obstet Gynecol 2009;114:65068) D espite considerable clinical and research effort directed toward the prevention of prematurity, preterm birth complicated 12.8% of pregnancies in the United States in 2006, a rise of 36% from the 9.4% incidence rate in the 1981. 1 Preterm birth is critically important as it results directly in acute neonatal morbidities and mortality. 2 Long-term se- quelae, including neurologic handicap, blindness, deafness, and chronic respiratory disease are di- rectly linked to preterm birth and its complications and are particularly more likely among neonates born before 32 weeks or under 1,500 grams. 35 Approximately 75% of preterm births result from spontaneous preterm labor or preterm premature rupture of the membranes before labor, with half or more of these resulting from preterm labor with intact membranes. 68 Given that more than 500,000 preterm births occur annually in the United States and that approximately half the women treated for See related editorial on page 500. From the Department of Obstetrics & Gynecology, MetroHealth Medical Center, Cleveland, Ohio. Continuing medical education for this article is available at http://links.lww. com/AOG/A120. The practice of medicine continues to evolve and individual circumstances will vary. This opinion reflects information available at the time of its acceptance for publication, and is neither designed nor intended to establish an exclusive standard of perinatal care. This publication is not expected to reflect the opinions of all members of the Society for MaternalFetal Medicine. Corresponding author: Brian M. Mercer, MD, Professor, Reproductive Biology, Case Western Reserve University, Vice-Chair, Director of Obstetrics & Mater- nal-Fetal Medicine, Department of Obstetrics & Gynecology, MetroHealth Medical Center, Suite G240, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109. Financial Disclosure The authors did not report any potential conflicts of interest. 2009 by The American College of Obstetricians and Gynecologists. Published by Lippincott Williams & Wilkins. ISSN: 0029-7844/09 650 VOL. 114, NO. 3, SEPTEMBER 2009 OBSTETRICS & GYNECOLOGY preterm labor will ultimately deliver at term, hun- dreds of thousands of women are evaluated and treated for preterm labor each year. Tocolytic therapy to prolong pregnancy and reduce newborn complications continues to be the focus of treat- ment of preterm labor. 916 Magnesium sulfate has been one of the most commonly used agents for this indication. The potential role of magnesium sulfate for neuroprotection of infants born preterm has also been recently studied. The purpose of this article is to review the physiology of magnesium, to evaluate the clinical utility of magnesium sulfate therapy for treatment of women presenting with preterm labor, and to con- sider the potential role of magnesium sulfate for neuroprotection when preterm birth is anticipated. This review focuses on the currently available peer- reviewed, randomized controlled trials evaluating the effectiveness of acute tocolysis, as well as those re- garding magnesium sulfate for neuroprotection when preterm birth is anticipated. PHYSIOLOGY OF MAGNESIUM SULFATE Several recent articles have reviewed the molecular and cellular physiology of magnesium in detail. 1723 Magnesium, a bivalent cation, is the fourth most common cation in the human body after sodium, potassium, and calcium. It is the second most com- mon intracellular cation after potassium. Intracellular magnesium is found predominantly in bone (53%) and in myocytes (27%) 17 and is localized to the nucleus, microsomes, and mitochondria. 18 Only 1% of total body magnesium is found extracellularly, 19 with serum magnesium accounting for 0.3% of total body magnesium content. 17 Approximately 62% of serum magnesium circulates in its ionized form. 17 The nor- mal serum magnesium level is 0.750.95 mmol/L (1.82.3 mg/dL). 19 Serum magnesium levels decline in pregnancy, likely due in part to hemodilution. 20,21 Magnesium transport across cell membranes is largely carrier-mediated, is coupled to sodium transport, and is energy requiring. Magnesium ex- cretion occurs primarily through the urinary tract with passive glomerular filtration. Approximately 65% of filtered magnesium is actively reabsorbed in the Loop of Henle, and 2030% is passively reab- sorbed in the proximal convoluted tubules. 23 In addition to serving as a cofactor for numerous reactions, including energy metabolism and nucleic acid synthesis, magnesium is implicated in regula- tion of adenylate cyclase, transmembrane ion flux, muscle contraction and neuronal activity, as well as control of vasomotor tone, cardiac excitability, and neurotransmitter release. 22 Magnesium sulfate is known to reduce spontaneous and induced myo- metrial contractions. 24,25 Magnesium is believed to affect contractility by competing with calcium in the sarcoplasmic reticulum, reducing the availabil- ity of calcium to participate in actinmyosin inter- action and in myometrial repolarization. Magne- sium is thought to act through both intracellular and extracellular mechanisms resulting in de- creased intracellular calcium availability by block- ing channel-dependent influx of extracellular cal- cium and also by blocking agonist-stimulated release of intracellular calcium via inositol 1,4,5- triphosphate receptor/channels. 26,27 In vitro, mag- nesium sulfate has been demonstrated to reduce spontaneous myometrial contractions at concentra- tions of 23 mmol (46 mEq/L), but suprapharma- cologic levels (410 mmol, 816 mEq/L) have been required to inhibit agonist mediated cyclic uterine activity. 2628 Magnesium has been shown to potentiate neuromuscular blockade from non- depolarizing agents, such as vecuronium and pancuronium. Potential mechanisms of perinatal brain injury related to ischemia, infection and inflammation, and hemorrhage are described in recent reviews by Berger et al, 29 Fawcett et al, 22 and Wolfe et al. 18 Although animal studies have suggested that mag- nesium can reduce ischemia-induced cellular injury and magnesium is known to be intricately involved in numerous cellular processes, the mechanisms by which magnesium might reduce or prevent neuro- nal damage have not been fully elucidated. Magne- sium has been shown to antagonize N-methyl-D- aspartate regulated receptor activity, and thus high levels of magnesium might reduce post-trauma neuronal damage related to increased intracellular calcium. N-methyl-D-aspartate receptormediated attenuation of the decline in post-traumatic reduc- tion in intracellular magnesium levels has been associated with improved neurological outcome in rats. Another potential mechanism is the reduction of inositol 1,4,5-triphosphate receptor binding. Magnesium deficiency has been associated with reductions of antioxidant defenses and is associated with oxidative neuronal, myocardial, and endothe- lial death. However, magnesium deficiency has also been associated with both increased and decreased cellular apoptosis. Thus, while it is plausible that magnesium sulfate could provide neuroprotection through mechanisms such as reduced vascular in- stability and hypoxic damage, and/or reductions in cytokine/excitatory amino acidinduced damage, VOL. 114, NO. 3, SEPTEMBER 2009 Mercer and Merlino Magnesium Sulfate for Preterm Labor 651 Table 1. Nineteen Included Randomized Clinical Trials of Intravenous Magnesium Sulfate Tocolysis for Preterm Labor Published in English-Language Peer-Reviewed Journals Study, Year Gestational Age (wk) Major Inclusion Criteria Primary Control Group Treatment Compared with control Cotton et al, 32 1984 2634 Contractions, three or more in 10 min, and progressive cervical dilatation or 2 or more cm dilation or 80% or more effaced or SROM Dextrose placebo Cox et al, 33 1990 2434 Regular contractions and cervix between 1 and 5 cm Saline placebo Fox et al, 34 1993 3437 Preterm labor with cervical change Sedation/hydration How et al, 35 2006 3234 Contractions, six or more per h with progressive cervical dilatation or effacement No tocolysis Compared with -mimetics Miller et al, 36 1982 Less than 37 Contractions, every 5 min or less for 1 h and estimated fetal weight less than 2,500 g Terbutaline Cotton et al, 32 1984 2634 Contractions, three in 10 min, and progressive cervical dilatation or 2 or more cm dilation or 80% or more effaced or SROM Terbutaline Hollander et al, 37 1987 2035 Contractions, at least two in 10 min, and 30-s duration, with cervical change or with cervix 2 or more cm in nulliparas Ritodrine Wilkins et al, 38 1988 2536 Contractions, every 5 min with cervix 50% or more effaced or 2 or more cm dilated Ritodrine Chau et al, 39 1992 2335 Contractions, three or more in 10 min after initial measures or with cervix 80% or more effaced or two or more cm dilated Terbutaline Compared with calcium channel blockers Floyd et al, 40 1992 2034 Contractions, regular every 10 min or less with cervix 2 cm or more or with cervical change from prior examination Nifedipine Glock and Morales, 41 1993 2033 Contractions, regular every 10 min or less with cervical change, or regular contractions with cervix 2 or more cm Nifedipine Haghighi, 42 1999 2336 Contractions, every 10 min or less Nifedipine 652 Mercer and Merlino Magnesium Sulfate for Preterm Labor OBSTETRICS & GYNECOLOGY Method of Randomization and Concealment Treatments Alternative Rescue Therapy Three-armed trial, randomization method unclear MgSO 4 ; 4-g bolus then 2 g/h until quiescence for 12 h (48 h if SROM) Dextrose 5% at 125 mL/h No Random number table, sealed opaque envelopes MgSO 4 ; 4-g bolus then 2 g/h, increased to maximum of 3 g/h, continued for 24 h Saline 80 mL/h No Random number table, sealed opaque envelopes MgSO 4 ; 4-g bolus then 2 g/h, increased to maximum of 4 g/h, until successful Not stated Random number table, sealed opaque envelopes MgSO 4 ; 6-g bolus then 2 g/h, increased to maximum of 5 g/h until quiescence, for 24 h No Randomization method unclear, sealed envelopes MgSO 4 ; 4-g bolus then 2 g/h for 2 h, then 1 g/h for 22 h Terbutaline, 0.25 mg intravenously then 10 microgram/ min increased to maximum of 25 microgram/min Not stated 3-armed trial, randomization method unclear MgSO 4 ; 4-g bolus then 2 g/h until quiescence for 12 h (48 h if SROM) Terbutaline 9.2 microgram/min intravenously, increased to max 25.3 microgram/min No Random number table MgSO 4 ; 4-g bolus then 2 g/h, increased as needed to serum level 68 mg/dL, continued for 12 h Alternate regimen Ritodrine, 100 microgram/min intravenously, increased to maximum of 350 microgram/min, continued for 12 h Random number table, sealed opaque envelopes MgSO 4 ; 4-g bolus then 2 g/h, increased as needed to serum level 58 mg/dL, continued for 24 h after quiescence Alternate regimen Ritodrine 100 microgram/min intravenously, increased to maximum of 350 microgram/min, continued for 12 h after quiescence Pseudo-randomization by medical record number MgSO 4 ; 4-g bolus then 2 g/h, increased to maximum of 4 g/h, until quiescence for 12 h or up to 24 h Mg level maintained between 4 and 7 mg/dL Alternate regimen Terbutaline, 0.25 mg subcutaneously every 30 min for three doses, then every 4 h until quiescence for 12 h or up to 24 h Random number table, sealed opaque envelopes MgSO 4 ; 4-g bolus then 4-6 g/h as needed, continued for 6 h after quiescence Nifedipine, 30 mg by mouth then 20 mg every 8 h until quiescence Not stated Randomization method unclear MgSO 4 ; 6-g bolus then 2 g/h, increased to maximum of 4 g/h, until quiescence for 24 h Nifedipine, 10 mg sublingual repeated every 20 min to maximum of 40 mg, then 20 mg by mouth every 4 h for 48 h Intravenous ritodrine Randomization method unclear MgSO 4 ; 6-g bolus then 2 g/h, increased to maximum of 4 g/h, until quiescence for 12 h Nifedipine, 10 mg sublingual repeated every 20 min to maximum of 40 mg, then 20 mg by mouth every 6 h for 24 h, then 20 mg every 8 h for 24 h Not stated (continued) VOL. 114, NO. 3, SEPTEMBER 2009 Mercer and Merlino Magnesium Sulfate for Preterm Labor 653 further study is needed to clarify its role in these processes. TOCOLYSIS FOR TREATMENT OF PRETERM LABOR Magnesium sulfate has been evaluated and used for its tocolytic properties for nearly 50 years. 25,30 Typ- ically a 4- to 6-g loading dose over 1530 minutes is followed by a continuous infusion of 2 g/h, and this infusion may be increased up to 45 g/h as needed in the absence of significant clinical side effects or oliguria. Magnesium toxicity is rarely seen with serum levels below 10 mg/dL, but respiratory depression and subsequent arrest can occur at levels above 1012 mg/dL. Although serious com- plications rarely occur during magnesium sulfate tocolysis, other side effects, including lethargy, flushing, nausea and vomiting, blurred vision and dizziness, are not uncommon, occurring in 1329% of patients in one report. 31 Magnesium sulfate has been the subject of numerous clinical trials regarding its efficacy for the treatment of preterm labor. Individual studies have been marked by inadequate power to evaluate the impact of treatment on neonatal outcomes, the primary reason for which pregnancy prolongation is attempted. Other than -mimetics, most tocolytic agents have not been tested extensively against a placebo or control group, and magnesium sulfate is not an exception in this regard. Magnesium sulfate has been compared with a wide variety of agents, including alcohol, -mimetic agents, cyclooxygen- ase inhibitors, calcium channel blockers, and nitric oxide donors. Like other tocolytic agents, compar- Table 1. Nineteen Included Randomized Clinical Trials of Intravenous Magnesium Sulfate Tocolysis for Preterm Labor Published in English-Language Peer-Reviewed Journals (continued) Study, Year Gestational Age (wk) Major Inclusion Criteria Primary Control Group Treatment Larmon et al, 43 1999 2434 Regular contractions, four or more per h for 1 h or more with cervical change Nicardipine Lyell et al, 31 2007 2433 Contractions, two or more every 10 min and cervical change, or SROM, or 2 or more cm dilated and 80% or more effaced Nifedipine Compared with cyclooxygenase inhibitors Morales and Madhav, 44 1993 Less than 32 Regular contractions, four or more in 20 min and progressive cervical dilatation or effacement, or cervix 2 or more cm dilated Indomethacin Parilla et al, 45 1997 Less than 30 Regular contractions with progressive cervical dilatation and effacement Indomethacin Schorr et al, 46 1998 2032 Regular contractions 12 or more in 60 min with cervix 50% or more effaced, 2 or more cm dilated or cervical change from a recent examination Ketolorac McWhorter et al, 47 2004 2234 Regular contractions with progressive cervical dilatation or effacement Rofecoxib Borna and Saeidi, 48 2008 2434 Contractions, four or more in 20 min or eight in 60 min with progressive cervical change in dilation or effacement Celecoxib Compared with alcohol Steer and Petrie, 49 1977 Less than 37 Painful contractions every 5 min or less Ethanol SROM, spontaneous rupture of the membranes; MgSO 4 , magnesium sulfate. 654 Mercer and Merlino Magnesium Sulfate for Preterm Labor OBSTETRICS & GYNECOLOGY ison of individual studies regarding magnesium sulfate is made difficult by varying inclusion re- quirements (eg, diagnostic criteria for preterm la- bor, gestational age, the presence or absence of intact membranes), concurrent interventions, dif- fering criteria for successful treatment, and therapy for initial treatment failures, as well as selective reporting of maternal and newborn outcomes. These trials have been the subject of several re- views and meta-analyses, which provide detailed descriptions of the individual study designs and outcomes. 911 The most recent substantial update of the Cochrane systematic reviewregarding magnesiumsulfate tocolysis for preterm labor was published by Crowther et al in 2002. 9 Published and unpublished data from 23 trials in peer-reviewed journals and abstracts were evaluated and included more than 2,000 pregnancies. The authors concluded that there was no evidence of a clinically important tocolytic effect for magnesium sulphate; it did not have any substantial effect on the proportion of women delivering within 48 hours, either overall, or in any subgroup analysis. Moreover, there was no evi- dence of any substantial improvements in neonatal morbidity. Alternatively, in an evidence report on the management of preterm labor, Berkman et al 10,11 eval- uated 18 randomized controlled trials and observational and retrospective studies. Regarding magnesium as a first-line treatment, this group determined that signifi- cant differences were not found between magnesium sulfate and placebo, but regarding comparisons among different classes of tocolytics, -mimetics, calcium Method of Randomization and Concealment Treatments Alternative Rescue Therapy Random number table, sealed opaque envelopes MgSO 4 ; 6-g bolus then 2 g/h, increased to maximum of 4 g/h, until quiescence Nicardipine, 40 mg by mouth, repeated every 2 h as required to maximum of 80 mg, then sustained release nicardipine 45 mg every 12 h Permitted but unspecified Random number table, sealed opaque envelopes MgSO 4 ; 4-g bolus then 2 g/h, increased to maximum of 4 g/h, until quiescence for 12 h Nifedipine, 10 mg sublingual repeated every 20 min to maximum of 80 mg, then 20 mg by mouth every 4 to 6 h until quiescence for 12 h Alternate regimen Random number table, sealed opaque envelopes MgSO 4 ; 6-g bolus then 2 g/h, increased to maximum of 5 g/h, until quiescence for 12 h Indomethacin, 100 mg rectally, repeated one time as needed after 1 h, then 25 mg by mouth every 4 h for 48 h Alternate regimen Random number table, sealed opaque envelopes with cross-over MgSO 4 ; 8 g over 1 h, then 4 g over 4 h, then 2.5 g/h, until quiescence for 12 h Permitted but unspecified Indomethacin, 50 or 100 mg by mouth or rectally, then 2550 mg by mouth every 46 h for 2448 h Randomization unclear, sealed opaque envelopes controlled by pharmacy MgSO 4 ; 6-g bolus then 2 g/h, increased to maximum of 6 g/h, and tapered until discontinued after quiescence achieved Not stated Ketolorac 60 mg intramuscularly then 30 mg intramuscularly every 6 h as needed for up to 24 h Random number table controlled by pharmacy MgSO 4 ; 4- to 6-g bolus then 24 g/h, for up to 48 h if needed Permitted but unspecified Rofecoxib 50 g by mouth daily for up to 48 h if needed Random number table controlled by pharmacy MgSO 4 ; 4- to 6-g bolus then 24 g/h, for up to 48 h if needed Celecoxib 100 g by mouth twice daily for up to 48 h if needed Permitted but unspecified Pseudo-randomization by medical record number. A saline control group chosen at random and was not evaluated MgSO 4 ; 4-g bolus then 2 g/h until labor subsided 9.5% ethanol, 15 mL/kg over 2 h then 1.5 mg/kg until labor subsided Not stated VOL. 114, NO. 3, SEPTEMBER 2009 Mercer and Merlino Magnesium Sulfate for Preterm Labor 655 channel blockers, and magnesium sulfate nearly dou- bled the odds of term births, relative to control, with potentially small differences in effect sizes between classes. These authors concluded that Overall, the evidence supports the notion that first-line treatment with -mimetics, calcium channel blockers, magnesium sulfate, or [nonsteroidal antiinflammatory drugs] offers small improvements in prolonging pregnancy. Due to the publication of an additional four trials regarding magnesium sulfate as a first-line tocolytic agent for preterm labor since the most recent Cochrane review, an additional analysis was performed for this review. METHODS OF SYSTEMATIC REVIEW Data Sources All English-language randomized clinical trials of magnesium sulfate tocolysis compared with an alter- nate tocolytic regimen or control therapy for preterm labor were identified through literature review. For this analysis, PubMed (U.S. National Library of Med- icine) was searched for English-language randomized controlled trials including the terms tocolysis and any of magnesium, indomethacin, prostaglan- din, COX, cyclo-oxygenase, nitric oxide, NO, calcium, oxytocin receptor antagonist, atosiban, betamimetic, and -agonist that were published between January 1, 1966, and December 31, 2008. The most recent Cochrane reviews regard- ing acute tocolysis with magnesium sulfate, tocolysis with other agents, and the above mentioned Agency for Healthcare Research and Quality report were reviewed for additional studies. 916 Study Selection and Data Abstraction Studies were excluded if magnesium was given in addition to or following failure of another tocolytic agent, was compared with a control group which included more than one agent, was compared with unspecified treatments at the discretion of the care- giver, or was given only to women with ruptured membranes. Studies of chronic prophylactic toco- lysis administered for the purpose of preventing, rather than treating, preterm labor were also ex- cluded. Data abstraction was performed only from the original peer-reviewed publications. The authors of the original articles were not contacted. Unpublished data used in other meta-analyses were not included. Each data point for all included articles was evaluated separately by two independent reviewers (B.M. and A.M.) who were masked to the others determination. These results were then compared, and all discrepan- cies were resolved by mutual re-review of the relevant manuscript. Subsequently, the results of our data review were compared with those from the most recent Cochrane analysis for those studies that were included in both, and each manuscript for which there was a discrepancy was again reviewed to make a final determination for each outcome. Selection of Outcomes Pregnancy latency characteristics, including gesta- tional age at randomization and delivery, latency to delivery, and various markers of early delivery and preterm birth (before 48 hours and 7 days, before 32, 34, and 37 weeks) and low birth weight (below 2,500 g) were evaluated for each included article where available. Perinatal outcomes (fetal and/or newborn mortality before discharge, major acute morbidities before discharge) were also analyzed. Statistical Analyses Statistical analyses were performed using Review Manager (RevMan) 5.0 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008) and figures were adapted from Forest plots obtained using this software (forest plots are available online at http://links.lww.com/AOG/A121). Mantel Haenszel 2 analyses, using a fixed effects model, were performed for categorical data. The DerSimo- nian-Laird random effects model was used for contin- uous data. Data are presented as summary relative risks (RRs) (95% confidence intervals [CIs]) for cate- gorical outcomes and as mean differences (95% CIs) for continuous variables. Where significant heteroge- neity was identified using the Q statistic, P values for the summary RRs and mean differences were not evaluated. Separate analyses were performed for tri- als comparing magnesium sulfate with a control/ placebo or no treatment, for trials comparing mag- nesium sulfate with alternate classes of tocolytic agents, and for all studies combined. Where a specific outcome was not evaluated in any of the compared trials, this outcome was excluded from the corresponding table. No sensitivity analyses were prespecified. Summary of Included and Excluded Articles Table 1 summarizes those published peer-reviewed studies regarding magnesium sulfate as a first-line tocolytic agent that were selected for inclusion. In four of these trials, magnesium sulfate was com- pared with a control/placebo or no additional tocolytic treatment. 3235 In 16 trials, magnesium sulfate tocolysis was compared with an alternate 656 Mercer and Merlino Magnesium Sulfate for Preterm Labor OBSTETRICS & GYNECOLOGY tocolytic regimen and had outcomes published relevant to the current analyses. 31,32,3649 In one trial, magnesium sulfate was compared with both a placebo group and a specific alternative tocolytic regimen. 32 Twelve studies utilized random number tables for study group assignment, while two studies used medical record numbers, and five did not specify the method of randomization (Table 1). Study group assignment was concealed by sealed opaque envelopes in nine studies. In three trials, the envelopes or random number table list was con- trolled by the study pharmacy. In the remaining seven studies, the concealment method was un- clear. Three of the trials included evaluation of maternal serum magnesium levels to determine adequacy of dosing. 3739 The included studies were inconsistent regarding the inclusion of twin preg- nancies and the method of presentation of their newborns outcomes. Some presented data for both twins while others presented only one set of new- born outcomes for each pregnancy, and these did not clarify whether the data were those for the first Table 2. Magnesium Sulfate Tocolysis Studies Not Included in the Current Analysis Study, Year Reason for Exclusion Aramayo et al, 50 1990 Magnesium sulfate versus terbutaline, published in Spanish Armson et al, 51 1992 Magnesium sulfate versus ritodrine, preterm deliveries excluded, no meaningful outcome data Beall et al, 52 1985 Magnesium sulfate versus -mimetics, outcomes assigned to last therapy rather than to assigned study group El-Sayed et al, 53 1999 Magnesium sulfate versus nitroglycerin, randomized by shuffling sealed opaque envelopes, outcomes specific to this analysis not reported Ferguson et al, 54 1984 Combination therapy, magnesium sulfate adjuvant to ritodrine Hatjis et al, 55 1987 Combination therapy, magnesium sulfate adjuvant to ritodrine How et al, 56 1998 All patients had preterm premature rupture of the membranes and not all were contracting Ma, 57 1992 Magnesium sulfate versus barbiturates, published in Chinese Mittendorf et al, 58 2002 Control group received caregivers choice of ritodrine, terbutaline, indomethacin or nifedipine for acute tocolysis Newton et al, 59 1991 Magnesium sulfate alone versus magnesium sulfate in combination with indomethacin and antibiotics Ogburn et al, 60 1985 Magnesium sulfate as adjuvant for primary tocolytic failure Sciscione et al, 61 1993 Abstract only, no peer reviewed manuscript Tchilinguirian et al, 62 1984 Randomization method unclear, outcomes specific to this analysis not reported Weiner et al, 63 1998 All patients had premature rupture of the membranes, no distinct magnesium sulfate treatment group Wischnik et al, 64 1989 Combination therapy with another tocolytic (fenoterol), published in German Zhu and Fu, 65 1996 Magnesium sulfate versus ritodrine, published in Chinese Table 3. Pregnancy and Newborn Outcomes After Magnesium Sulfate Treatment Compared With Control or No Therapy for Preterm Labor (Four Trials 3235 )* Outcome Studies Magnesium Sulfate [n/N (%)] Control [N (%)] Heterogeneity P Summary Relative Risk 95% Confidence Interval P for Overall Effect Delivery less than 48 h 3 32/85 (37.6) 46/94 (48.9) .46 0.75 0.541.03 .07 Delivery less than 7 d 3 57/116 (49.1) 52/129 (40.3) .47 1.22 0.941.59 .14 Delivery less than 37 wk 2 32/40 (80.0) 33/49 (67.3) .27 1.18 0.931.51 .17 Birth weight less than 2,500 g 2 61/93 (65.6) 69/98 (70.4) .54 0.94 0.781.14 .53 Respiratory distress 4 22/159 (13.8) 22/173 (12.7) .94 1.10 0.661.85 .71 IVH 4 5/159 (3.1) 7/173 (4.0) .48 0.80 0.262.45 .69 Grade 34 IVH 2 0/69 (0) 0/75 (0) NA Necrotizing enterocolitis 4 4/159 (2.5) 4/173 (2.3) .49 1.09 0.303.97 .89 Sepsis/infection 1 2/15 (13.3) 0/19 (0) NA 6.25 0.32121.1 .23 Fetal death 4 2/161 (1.2) 0/173 (0) NA 5.13 0.25105.1 .29 Newborn death before discharge 4 7/159 (4.4) 6/173 (3.5) .08 1.33 0.453.92 .61 Fetal or newborn death before discharge 4 9/161 (5.6) 6/173 (3.5) .05 1.68 0.604.70 .33 IVH, intraventricular hemorrhage; NA, not applicable. * Comparison of magnesium sulfate with placebo from Cotton et al 32 used for this analysis. VOL. 114, NO. 3, SEPTEMBER 2009 Mercer and Merlino Magnesium Sulfate for Preterm Labor 657 twin, the second twin, a randomly selected twin, or for the worst outcome for either twin. Newborn outcome data were analyzed as published in the primary papers. Postrandomization exclusion and loss to follow-up were uncommon (less than 5%) in all studies with the exception of one in which 13 of 114 recruited patients were excluded after random- ization. 44 Sixteen additional studies were consid- ered but were excluded from further analysis based on criteria delineated in Table 2. 5065 Results of analyses from the included trials are presented in Tables 310 and Figures 15. SUMMARY OF RESULTS Magnesium Sulfate Compared With Control or No Therapy A major purported benefit of acute tocolysis for preterm labor is brief pregnancy prolongation to allow administration of antenatal corticosteroids for fetal maturation. Data in this regard were frequently available in published trials, with 12 of 19 evaluated studies reporting the outcome of delivery within 48 hours for a total of 1,281 pregnancies. However, only three of four studies that compared magnesium sulfate with a placebo/control or no therapy evaluated the impact of such treatment on delivery within 48 hours or within 7 days (Table 3). 3235 These trials appeared to include higher-risk populations than the trials compar- ing magnesium sulfate with an alternative tocolytic regimen, with more frequent early delivery and preterm birth. Overall, magnesium sulfate tocolysis did not re- duce the frequency of delivery within 48 hours when compared with placebo/control or no tocolytic treat- ment (RR 0.75 [0.541.03]) (Table 3 and Fig. 1). No significant reductions in delivery within 7 days or before 37 weeks of gestation were evident with magnesium sulfate tocolysis, and no trend toward reduction in the outcome of newborn birth weight below 2,500 g was seen (Table 3 and Fig. 2). No individual study demon- strated improvements in these outcomes with magne- siumsulfate tocolysis. Significant heterogeneity was seen regarding latency to delivery and delivery gestation, but no improvement in newborn birth weight was seen with magnesium treatment (Table 4). Table 4. Gestational Age, Latency, and Birth Weight Outcomes After Magnesium Sulfate Treatment Compared With Control or No Therapy for Preterm Labor (Four Trials 3235 )* Outcome Studies Magnesium (N) Control (N) Heterogeneity P Mean Difference 95% Confidence Interval P for Overall Effect Gestation at enrollment (wk) 4 161 174 .05 0.02 0.28 to 0.25 .91 Latency (wk) 4 161 174 .001 0.29 1.21 to 0.63 Gestation at delivery (wk) 4 160 174 .001 0.48 1.81 to 0.86 Birth weight (g) 4 161 173 .09 28.6 179.1 to 121.8 .71 * Comparison of magnesium sulfate with placebo from Cotton et al 32 used for this analysis. Table 5. Pregnancy and Newborn Outcomes After Magnesium Sulfate Treatment Compared With -mimetics for Preterm Labor (Five Trials 32,3639 )* Outcome Studies Magnesium Sulfate [n/N (%)] Control [n/N (%)] Heterogeneity P Summary Relative Risk 95% Confidence Interval P for Overall Effect Delivery less than 48 h 3 17/128 (13.3) 15/125 (12.0) .52 1.23 0.702.17 .47 Delivery less than 7 d 5 40/176 (22.7) 44/176 (25.0) .32 0.94 0.681.31 .73 Delivery less than 37 wk 4 67/142 (47.2) 76/140 (54.3) .12 0.87 0.691.08 .21 Birth weight less than 2,500 g 2 23/31 (74.2) 27/35 (77.1) .85 0.98 0.761.25 .84 Respiratory distress 2 9/30 (30.0) 6/35 (17.1) .86 1.79 0.734.41 .20 IVH 1 1/15 (6.7) 2/19 (10.5) NA 0.63 0.066.34 .70 Necrotizing enterocolitis 1 0/15 (0) 1/19 (5.3) NA 0.42 0.029.55 .58 Sepsis/infection 1 2/15 (13.3) 7/19 (36.8) NA 0.36 0.091.49 .16 Fetal death 1 0/15 (0) 0/19 (0) NA Newborn death before discharge 1 1/15 (6.7) 1/19 (5.3) NA 1.27 0.0918.6 .86 Fetal or newborn death before discharge 1 1/15 (6.7) 1/19 (5.3) NA 1.27 0.0918.6 .86 IVH, intraventricular hemorrhage; NA, not applicable. * Comparison of magnesium sulfate with terbutaline from Cotton et al 32 used for this analysis. 658 Mercer and Merlino Magnesium Sulfate for Preterm Labor OBSTETRICS & GYNECOLOGY The 2002 Cochrane review regarding this issue also found that magnesium sulfate tocolysis did not signifi- cantly prolong pregnancy at 48 hours or 7 days or prevent pretermbirth. 9 That analysis included data from a study of magnesium sulfate compared with sedation alone, which found delivery at 48 hours to be less common with magnesium sulfate therapy (23.3% com- pared with 91.4%, N65). 57 However, inclusion of this trial into our analysis would have led to a result with significant heterogeneity (data not shown). Consistent with lack of evident benefit of magne- sium sulfate tocolysis for pregnancy prolongation, we found no improvements in perinatal mortality (fetal death and/or newborn death before discharge) or the most common perinatal morbidities (respiratory dis- tress, intraventricular hemorrhage, severe intraventricu- lar hemorrhage, necrotizing enterocolitis, newborn sep- sis) when magnesium sulfate was compared with a placebo/control or no therapy (Table 3 and Figs. 35). No individual study demonstrated improved outcomes with magnesium sulfate for any of the newborn outcomes. Magnesium Sulfate Compared With Other Tocolytic Classes Given the above findings, the question remains as to whether alternative tocolytic classes might be more effective than magnesium sulfate. Separate evalua- tions were performed for head-to-head trials in which magnesium was compared with a distinct alternative tocolytic class. Magnesium sulfate was compared with -mimetics in five studies, calcium channel blockers in five studies, and cyclooxygenase inhibitors in five studies. (Table 1). The results of these analyses are summarized in Tables 510. Data available from individual trials for selected outcomes are presented in Figs. 15. Compared with magnesium sulfate, -mimetic treatment was not associated with reduc- tions in delivery at 48 hours, 7 days, preterm birth, or low birth weight, despite an apparent improvement in overall latency in two studies (Tables 5 and 6). 32,3639 Compared with magnesium sulfate, calcium channel blocker therapy did not improve any marker of latency, prematurity, or gestational age at delivery Table 6. Gestational Age, Latency and Birth Weight Outcomes After Magnesium Sulfate Treatment Compared With -mimetics for Preterm Labor (Five Trials 32,3639 )* Outcome Studies Magnesium (N) Control (N) Heterogeneity P Mean Difference 95% Confidence Interval P for Overall Effect Gestation at enrollment (wk) 4 142 140 .55 0.30 0.89 to 0.29 .32 Latency (wk) 2 61 71 .37 1.57 0.74 to 2.41 .001 Gestation at delivery (wk) 1 15 19 NA 2.10 3.87 to 0.33 .02 Birth weight (g) 2 61 71 .07 76.4 385.6 to 538.5 .75 NA, not applicable. * Comparison of magnesium sulfate versus terbutaline from Cotton et al 32 used for this analysis. Table 7. Analysis of Pregnancy and Newborn Outcomes After Magnesium Sulfate Treatment Compared With Calcium Channel Blockers for Preterm Labor (Five Trials 31,4043 ) Outcome Studies Magnesium Sulfate [n/N (%)] Control [n/N (%)] Heterogeneity P Summary Relative Risk 95% Confidence Interval P for Overall Effect Delivery less than 48 h 4 26/238 (10.9) 23/230 (10.0) .95 1.06 0.631.78 .84 Delivery less than 37 wk 3 92/173 (53.2) 93/189 (49.2) .76 1.07 0.881.30 .52 Delivery less than 34 wk 2 21/81 (25.9) 25/89 (28.1) .71 0.89 0.551.45 .64 Delivery less than 32 wk 1 10/92 (10.9) 7/100 (7.0) NA 1.55 0.623.91 .35 Birth weight less than 2,500 g 2 71/146 (48.6) 60/160 (37.5) .25 1.29 0.991.67 .06 Respiratory distress 2 28/146 (19.2) 26/159 (16.4) .78 1.15 0.711.86 .57 IVH 1 3/106 (2.8) 2/110 (1.8) NA 1.56 0.279.13 .62 Necrotizing enterocolitis 1 0/106 (0) 0/110 (0) NA Sepsis/infection 1 5/106 (4.7) 3/110 (2.7) NA 1.73 0.427.06 .45 Fetal death 3 0/146 (0) 1/146 (0.7) NA 0.41 0.029.91 .59 Newborn death before discharge 4 1/252 (0.4) 3/256 (1.2) .44 0.59 0.132.70 .49 Fetal or newborn death before discharge 3 0/146 (0) 3/146 (2.1) .73 0.27 0.032.29 .23 NA, not applicable; IVH, intraventricular hemorrhage. VOL. 114, NO. 3, SEPTEMBER 2009 Mercer and Merlino Magnesium Sulfate for Preterm Labor 659 and did not prevent adverse newborn outcomes in studies totaling more than 550 pregnancies (Tables 7 and 8). 31,4043 Similarly, treatment with cyclooxygen- ase inhibitors did not appear to confer any benefits over magnesium sulfate therapy (Tables 9 and 10). 4448 Comparison of perinatal morbidities accord- ing to tocolytic classes was limited in some cases because these results were not included in all studies and/or the frequency of adverse outcomes was low. No individual tocolytic class was more effective than magnesium sulfate in preventing any of the evaluated newborn morbidities or fetal/newborn mortality be- fore discharge (Tables 5, 7, and 9). Review of trials not included in the statistical analyses found more frequent successful tocolysis at 12 hours with magnesium sulfate than with nitroglyc- erin (78.6 compared with 37.5%, P.03) and frequent hypotension requiring discontinuation of nitroglyc- erin (25%), but other outcomes relevant to this anal- ysis were not published. 53 In a comparison of magne- sium sulfate and ritodrine in 67 women, Tchilinguirian et al 62 identified failed tocolysis within 48 hours to be similarly common between groups (25% compared with 35.5%, P.35), but data regard- ing timing of delivery and other outcomes specific to this analysis were not provided. In an evaluation of seven studies, the Cochrane review found an increased risk of total fetal, neonatal, and/or neonatal deaths with magnesium tocolysis (RR 2.82 [1.206.62]). However, there was no con- sistent pattern between studies. We found no in- creases in fetal or newborn death before discharge (RR 1.08 [0.472.46) with magnesium sulfate therapy compared with any alternative regimen. We did not include the trial by Mittendorf et al 58 because of the lack of a distinct control intervention (caregivers choice). Had we included this study in our analysis, our finding of no evident increase in total death before discharge would not have been altered (18 of 414 magnesium sulfate versus 10 of 420 control in nine trials, RR 1.78 [0.863.70]). Efficacy of Other Tocolytic Agents Detailed evaluation of the literature regarding the efficacy other classes of tocolytic agents is beyond the scope of this article, and recent reviews regarding these have been published elsewhere. 9,1216 In the preceding analyses, individual classes of tocolytic Table 8. Gestational Age, Latency, and Birth Weight Outcomes After Magnesium Sulfate Treatment Compared With Calcium Channel Blockers for Preterm Labor (Five Trials 31,4043 ) Outcome Studies Magnesium (N) Control (N) Heterogeneity P Mean Difference 95% Confidence Interval P for Overall Effect Gestation at enrollment (wk) 3 173 189 .26 0.25 0.82 to 0.31 .38 Latency (wk) 2 105 107 .44 0.23 0.79 to 1.26 .66 Gestation at delivery (wk) 3 198 196 .52 0.05 0.59 to 0.69 .88 Birth weight (g) 4 252 240 .73 10.4 134.6 to 113.9 .87 Table 9. Pregnancy and Newborn Outcomes After Magnesium Sulfate Treatment Compared With Cyclooxygenase Inhibitors for Preterm Labor (Five Trials 4448 ) Outcome Studies Magnesium Sulfate [n/N (%)] Control [n/N (%)] Heterogeneity P Summary Relative Risk 95% Confidence Interval P for Overall Effect Delivery less than 48 h 3 21/205 (10.2) 25/207 (12.1) .43 0.84 0.491.45 .53 Delivery less than 37 wk 1 7/43 (16.3) 4/45 (8.9) NA 1.83 0.585.81 .30 Respiratory distress 4 33/215 (15.3) 30/200 (15.0) .79 0.99 0.631.55 .96 IVH 4 17/215 (7.9) 15/200 (7.5) .91 0.99 0.521.88 .98 Grade 34 IVH 2 2/70 (2.9) 1/63 (1.6) .66 1.44 0.1910.8 .72 Necrotizing enterocolitis 2 0/120 (0) 3/106 (2.8) .86 0.21 0.021.87 .16 Sepsis/infection 1 7/102 (6.9) 5/92 (5.4) NA 1.26 0.423.84 .68 Fetal death 1 0/52 (0) 0/49 (0) NA Newborn death before discharge 3 6/172 (1.8) 2/155 (1.3) .42 2.28 0.559.55 .26 Fetal or newborn death before discharge 1 1/52 (1.9) 1/49 (2.0) NA 0.94 0.0614.7 .97 NA, not applicable; IVH, intraventricular hemorrhage. 660 Mercer and Merlino Magnesium Sulfate for Preterm Labor OBSTETRICS & GYNECOLOGY agents were not superior to magnesium sulfate. When evaluated in aggregate, other tocolytic therapy was not superior to magnesium sulfate regarding latency, preterm birth, perinatal mortality, respiratory distress, or intraventricular hemorrhage. (Figs. 15). 31,32,3649 Data available from the most recent substantive Cochrane meta-analysis updates and subsequently published randomized controlled trials are gener- ally supportive of the findings obtained in the current analysis. In 2004, Anotayanonth et al 16 reported on 16 trials in which a -mimetic was compared with placebo or another -mimetic to inhibit preterm labor. Compared with placebo, -mimetic treatment reduced delivery within 48 hours (RR 0.63 [0.530.75]) and 7 days (RR 0.78 [0.680.90]), but no significant reductions in pre- term birth, respiratory distress, or other neonatal morbidities were evident. The only U.S. Food and Drug Administrationapproved tocolytic agent (in- travenous ritodrine; Yutopar, AstraZeneca, Lon- don, UK; NDA #018580) is no longer marketed in the United States. In a 2005 Cochrane review of 13 trials, King et al 12 found no improvements in neo- natal outcomes when cyclooxygenase inhibitors were compared with placebo (three trials) or with other agents, although cyclooxygenase treatment was associated with less frequent preterm birth, delivery within 48 hours, and delivery within 7 days, as well as improvements in gestational age at delivery and birth weight. 66,67 Meta-analysis regard- Control or placebo Cotton 1984 Fox 1993 How 2006 Subtotal (95% CI) 10 19 3 32 16 45 24 85 12 29 5 46 19 45 30 94 10.2 27.1 4.1 41.4 0.99 (0.591.65) 0.66 (0.440.98) 0.75 (0.202.83) 0.75 (0.541.03) Heterogeneity: df=2, P=.46 Test for overall effect: P=.07 Magnesium Events Total Control Events Total Weight (%) Risk ratio (95% CI) Delivery within 48 hours 0.05 0.2 1 5 20 Compared with other tocolytics Compared with any control Heterogeneity: df=9, P=.88 Heterogeneity: df=12, P=.79 Test for overall effect: P=.95 64 571 63 562 58.6 1.01 (0.741.38) Test for overall effect: P=.37 96 656 109 656 100.0 0.90 (0.721.13) 0.05 0.2 1 5 20 Betamimetics Cotton 1984 Wilkins 1988 Chau 1992 Subtotal (95% CI) 10 5 2 17 16 66 46 128 9 2 4 15 19 54 52 125 7.7 2.1 3.5 13.2 1.32 (0.722.42) 2.05 (0.4110.13) 0.57 (0.112.94) 1.23 (0.702.17) Heterogeneity: df=2, P=.52 Test for overall effect: P=.47 Calcium channel blockers Glock 1993 Larmon 1999 Haghighi 1999 Lyell 2007 Subtotal (95% CI) 3 4 12 7 26 41 65 40 92 238 3 4 8 8 23 39 57 34 100 230 2.9 4.0 8.1 7.2 22.1 0.95 (0.204.43) 0.88 (0.233.35) 1.27 (0.592.75) 0.95 (0.362.52) 1.06 (0.631.78) Heterogeneity: df=3, P=.95 Test for overall effect: P=.84 Cyclooxygenase inhibitors Morales 1993 McWhorter 2004 Borna 2008 Subtotal (95% CI) 8 6 7 21 52 101 52 205 5 10 10 25 49 106 52 207 4.8 9.1 9.3 23.2 1.51 (0.534.30) 0.63 (0.241.67) 0.70 (0.291.70) 0.84 (0.491.45) Heterogeneity: df=2, P=.43 Test for overall effect: P=.53 Fig. 1. Comparison of magnesium sulfate tocolysis and other regimens (control/no therapy, individual toco- lytic classes, any tocolytic agent, and any other regimen) for delivery within 48 hours. Modified from figures gen- erated by Review Manager 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. CI, confidence interval; df, de- grees of freedom. Mercer. Magnesium Sulfate for Preterm Labor. Obstet Gynecol 2009. Table 10. Gestational Age, Latency, and Birth Weight Outcomes After Magnesium Sulfate Treatment Versus Cyclooxygenase Inhibitors for Preterm Labor (Five Trials 4448 ) Outcome Studies Magnesium (N) Control (N) Heterogeneity P Mean Difference 95% Confidence Interval P for Overall Effect Gestation at enrollment (wk) 5 268 263 .10 0.50 0.02 to 0.98 .04 Latency (wk) 1 52 49 NA 0.03 0.72 to 0.66 .93 Gestation at delivery (wk) 4 209 201 .74 0.13 0.78 to 0.51 .68 Birth weight (g) 4 224 207 .34 83.1 53.2 to 219.4 .23 NA, not applicable. VOL. 114, NO. 3, SEPTEMBER 2009 Mercer and Merlino Magnesium Sulfate for Preterm Labor 661 ing nitric oxide donors and oxytocin receptor an- tagonists have failed to demonstrate improved pregnancy or neonatal outcomes with these classes of tocolytic agents. 14,15 Finally, calcium channel blocker treatment for preterm labor has garnered significant attention in recent years; however no Control or placebo Cotton 1984 How 2006 Subtotal (95% CI) 14 18 32 16 24 40 16 17 33 19 30 49 7.4 7.6 15.0 1.04 (0.791.36) 1.32 (0.901.95) 1.18 (0.931.51) Heterogeneity: df=1, P=.27 Test for overall effect: P=.17 Magnesium Events Total Control Events Total Weight (%) Risk ratio (95% CI) Delivery before 37 weeks Betamimetics Miller 1982 Cotton 1984 Wilkins 1988 Chau 1992 Subtotal (95% CI) Heterogeneity: df=3, P=.12 6 14 35 12 67 14 16 66 46 142 7 15 29 25 76 15 19 54 52 140 3.4 6.9 16.0 11.8 38.1 0.92 (0.412.07) 1.11 (0.821.49) 0.99 (0.711.38) 0.54 (0.310.95) 0.87 (0.691.08) Test for overall effect: P=.21 Calcium channel blockers Glock 1993 Floyd 1995 Lyell 2007 Subtotal (95% CI) Heterogeneity: df=2, P=.76 24 18 50 92 41 40 92 173 23 18 52 93 39 50 100 189 11.9 8.0 25.1 45.0 0.99 (0.691.43) 1.25 (0.762.07) 1.05 (0.801.36) 1.07 (0.881.30) Test for overall effect: P=.52 Cyclooxygenase inhibitors Schorr 1998 Subtotal (95% CI) 7 7 43 43 4 4 45 45 2.0 2.0 1.83 (0.585.81) 1.83 (0.585.81) Heterogeneity: Not applicable Test for overall effect: P=.30 Compared with other tocolytics Compared with any control Heterogeneity: df=7, P=.43 Heterogeneity: df=9, P=.47 Test for overall effect: P=.95 166 358 173 374 85.0 0.99 (0.861.15) Test for overall effect: P=.73 198 398 206 423 100.0 1.02 (0.901.17) 0.2 0.5 1 2 5 0.2 0.5 1 2 5 Fig. 2. Comparison of magnesium sulfate tocolysis and other regimens (control/no therapy, individual toco- lytic classes, any tocolytic agent, and any other regimen) for preterm deliv- ery before 37 weeks of gestation. Modified from figures generated by Review Manager 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. CI, confidence interval; df, degrees of freedom. Mercer. Magnesium Sulfate for Preterm Labor. Obstet Gynecol 2009. Control or placebo Cotton 1984a Cox 1990 Fox 1993 How 2006 Subtotal (95% CI) 1 8 0 0 9 15 77 45 24 161 4 2 0 0 6 19 79 45 30 173 31.2 17.5 48.6 0.32 (0.042.55) 4.10 (0.9018.71) Not estimable Not estimable 1.68 (0.604.70) Heterogeneity: df=1, P=.05 Test for overall effect: P=.33 Magnesium Events Total Control Events Total Weight (%) Risk ratio (95% CI) Fetal or newborn death before discharge Betamimetics Cotton 1984b Subtotal (95% CI) Heterogeneity: Not applicable 1 1 15 15 1 1 19 19 7.8 7.8 1.27 (0.0918.62) 1.27 (0.0918.62) Test for overall effect: P=.86 Calcium channel blockers Glock 1993 Floyd 1995 Larmon 1999 Subtotal (95% CI) Heterogeneity: df=1, P=.73 0 0 0 0 41 40 65 146 2 1 0 3 39 50 57 146 22.6 11.8 34.5 0.19 (0.013.85) 0.41 (0.029.91) Not estimable 0.27 (0.032.29) Test for overall effect: P=.23 Cyclooxygenase inhibitors Morales 1993 Subtotal (95% CI) 1 1 52 52 1 1 49 49 9.1 9.1 0.94 (0.0614.65) 0.94 (0.0614.65) Heterogeneity: Not applicable Test for overall effect: P=.97 Compared with other tocolytics Compared with any control Heterogeneity: df=3, P=.79 Heterogeneity: df=5, P=.31 Test for overall effect: P=.37 2 213 5 214 51.4 0.54 (0.142.09) Test for overall effect: P=.83 11 374 11 387 100.0 1.09 (0.502.41) 0.01 0.1 1 10 100 0.01 0.1 1 10 100 Fig. 3. Comparison of magnesium sulfate tocolysis and other regimens (control/no therapy, individual toco- lytic classes, any tocolytic agent, and any other regimen) for fetal or new- born death before discharge. Modi- fied fromfigures generated by Review Manager 5.0. Copenhagen: The Nor- dic Cochrane Centre, The Cochrane Collaboration, 2008. CI, confidence interval; df, degrees of freedom. Mercer. Magnesium Sulfate for Preterm Labor. Obstet Gynecol 2009. 662 Mercer and Merlino Magnesium Sulfate for Preterm Labor OBSTETRICS & GYNECOLOGY placebo-controlled studies or comparisons with no treatment have been published. In a 2003 Co- chrane meta-analysis of 12 trials, King et al 13 re- ported improved latency and reductions in neona- tal morbidities including respiratory distress, intraventricular hemorrhage, and necrotizing en- terocolitis with calcium channel blocker therapy. However, these improvements were largely due to Control or placebo Cotton 1984 Cox 1990 Fox 1993 How 2006 Subtotal (95% CI) 6 15 1 0 22 15 75 45 24 159 6 15 1 0 22 19 79 45 30 173 6.4 17.6 1.2 25.1 1.27 (0.513.14) 1.05 (0.552.00) 1.00 (0.0615.50) Not estimable 1.10 (0.661.85) Heterogeneity: df=2, P=.94 Test for overall effect: P=.71 Magnesium Events Total Control Events Total Weight (%) Risk ratio (95% CI) Respiratory distress 0.05 0.2 1 5 20 Betamimetics Miller 1982 Cotton 1984 Subtotal (95% CI) Heterogeneity: df=1, P=.86 3 6 9 15 15 30 2 4 6 16 19 35 2.3 4.2 6.6 1.60 (0.318.29) 1.90 (0.655.53) 1.79 (0.734.41) Test for overall effect: P=.20 Calcium channel blockers Floyd 1995 Lyell 2007 Subtotal (95% CI) Heterogeneity: df=1, P=.78 4 24 28 40 106 146 5 21 26 49 110 159 5.4 24.8 30.2 0.98 (0.283.41) 1.19 (0.702.00) 1.15 (0.711.86) Test for overall effect: P=.57 Cyclooxygenase inhibitors Morales 1993 Parilla 1997 Schorr 1998 McWhorter 2004 Subtotal (95% CI) 5 5 4 19 33 52 18 43 102 215 5 5 2 18 30 49 14 45 92 200 6.2 6.8 2.4 22.8 38.1 0.94 (0.293.06) 0.78 (0.282.17) 2.09 (0.4010.85) 0.95 (0.531.70) 0.99 (0.631.55) Heterogeneity: df=3, P=.79 Test for overall effect: P=.96 Compared with other tocolytics Compared with any control Heterogeneity: df=7, P=.92 Heterogeneity: df=10, P=.99 Test for overall effect: P=.45 70 391 62 394 74.9 1.12 (0.831.53) Test for overall effect: P=.40 92 550 84 567 100.0 1.12 (0.861.46) 0.05 0.2 1 5 20 Fig. 4. Comparison of magnesium sul- fate tocolysis and other regimens (con- trol/no therapy, individual tocolytic classes, any tocolytic agent, and any other regimen) for respiratory distress. Modified from figures generated by Re- view Manager 5.0. Copenhagen: The Nordic Cochrane Centre, The Co- chrane Collaboration, 2008. CI, confi- dence interval; df, dgrees of freedom. Mercer. Magnesium Sulfate for Preterm Labor. Obstet Gynecol 2009. Control or placebo Cotton 1984 Cox 1990 Fox 1993 How 2006 Subtotal (95% CI) 1 4 0 0 5 15 75 45 24 159 3 4 0 0 7 19 79 45 30 173 9.9 14.6 24.5 0.42 (0.053.66) 1.05 (0.274.06) Not estimable Not estimable 0.80 (0.262.45) Heterogeneity: df=1, P=.48 Test for overall effect: P=.69 Magnesium Events Total Control Events Total Weight (%) Risk ratio (95% CI) Intraventricular hemorrhage 0.05 0.2 1 5 20 Betamimetics Cotton 1984 Subtotal (95% CI) Heterogeneity: Not applicable 1 1 15 15 2 2 19 19 6.6 6.6 0.63 (0.066.34) 0.63 (0.066.34) Test for overall effect: P=.70 Calcium channel blockers Lyell 2007 Subtotal (95% CI) Heterogeneity: Not applicable 3 3 106 106 2 2 110 110 7.4 7.4 1.56 (0.279.13) 1.56 (0.279.13) Test for overall effect: P=.62 Cyclooxygenase inhibitors Morales 1993 Parilla 1997 Schorr 1998 McWhorter 2004 Subtotal (95% CI) 4 6 0 7 17 52 18 43 102 215 4 4 1 6 15 49 14 45 92 200 15.4 16.9 5.5 23.7 61.5 0.94 (0.253.56) 1.17 (0.413.35) 0.35 (0.018.33) 1.05 (0.373.02) 0.99 (0.521.88) Heterogeneity: df=3, P=.91 Test for overall effect: P=.98 Compared with other tocolytics Compared with any control Heterogeneity: df=5, P=.97 Heterogeneity: df=7, P=.98 Test for overall effect: P=.96 21 336 19 329 75.5 1.02 (0.571.81) Test for overall effect: P=.89 26 495 26 502 100.0 0.96 (0.581.61) 0.05 0.2 1 5 20 Fig. 5. Comparison of magnesium sul- fate tocolysis and other regimens (con- trol/no therapy, individual tocolytic classes, any tocolytic agent, and any other regimen) for intraventricular hem- orrhage. Modified from figures gener- ated by Review Manager 5.0. Copenha- gen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. CI, con- fidence interval; df, degrees of freedom. Mercer. Magnesium Sulfate for Preterm Labor. Obstet Gynecol 2009. VOL. 114, NO. 3, SEPTEMBER 2009 Mercer and Merlino Magnesium Sulfate for Preterm Labor 663 the results of only one trial. 68 No consistent pattern regarding improved outcomes was seen in the remaining 11 studies, and no significant improve- ments in latency or newborn morbidities are evi- dent with calcium channel blocker tocolysis if this study is excluded from that analysis (data not shown). Two subsequently published trials have revealed conflicting results regarding the potential benefits of calcium channel blockers. 31,69 Sublingual administration of nifedipine, the usual initial mode of administration in the published tocolysis trials, has been associated with serious cardiovascular effects when given for hypertension, and this mode of administration is not recommended in preg- nancy or U.S. Food and Drug Administration approved for treatment of preterm labor. Magnesium Sulfate for Neuroprotection A number of observational studies in humans and animal studies have evaluated the potential that pre- natal exposure to magnesium sulfate might reduce neurologic morbidities. 7074 In addition to studies of magnesium sulfate for seizure prophylaxis in preg- nancies complicated by preeclampsia, 75,76 four ran- domized trials have been specifically designed to evaluate magnesium sulfate for neuroprotection. 7781 Although each of these four neuroprotection trials failed to demonstrate significant improvements in the designated primary outcome, none found increased pediatric morbidities or mortality with magnesium sulfate treatment given for this indication. Addition- ally, these studies did find improvements in other important outcomes with prenatal magnesium sulfate exposure. Crowther et al, 78 in a placebo controlled trial of women considered likely to deliver within 24 hours and before 30 weeks of gestation (4-g intrave- nous magnesium sulfate bolus over 20 minutes fol- lowed by an infusion at 1 g/h until delivery or for up to 24 hours), found less frequent substantial gross motor dysfunction (3.4% compared with 6.6%; RR 0.51 [0.290.91]) and death or substantial motor gross motor dysfunction (17.0% compared with 22.7%; RR 0.75 [0.590.96]) with magnesium sulfate treatment. Marret et al 81 compared magnesium sulfate (4-g intravenous bolus over 30 minutes) with placebo for women in preterm labor before 33 weeks of gesta- tion and demonstrated reductions in death and/or gross motor dysfunction (25.6% compared with 30.8%; odds ratio 0.62 [0.410.93]) and in death and/or motor or cognitive dysfunction (34.9% compared with 40.5%; odds ratio 0.68 [0.470.99]) at 2-year follow-up. Rouse et al 80 studied women at 2431 6/7 weeks of gestation in whom spontaneous or indicated preterm birth was anticipated within 24 hours. Treatment included a 6-g intravenous bolus of magnesium sulfate over 20 to 30 minutes followed by an infusion of 2 g/h, which was discontinued if delivery was not considered imminent after 12 hours. Retreatment was given for threatened delivery before 34 weeks of gestation. Using this ap- proach, these investigators demonstrated less frequent moderate or severe cerebral palsy (1.9% compared with 3.5%; RR 0.55 [0.320.95]) and overall cerebral palsy (4.2% compared with 7.3%, P.004) in the magnesium sulfate arm. Comparisons between the published trials are made difficult by differences in inclusion criteria, study interventions, and evaluated outcomes. Although a 2009 meta-analysis was supportive of magnesium sulfate for neuroprotection before preterm birth, the optimal treatment indication(s), gestational age range, and therapeutic regimen remain to be determined. 82 SUMMARY Magnesium sulfate has been incorporated widely into obstetric practice as a tocolytic agent for preterm labor. Like other tocolytic agents, there is biologic plausibility to suggest that magnesium might act to interfere with uterine contractions by interference with intracellular calcium directly or via membrane calcium channels, and there is evidence that mag- nesium can reduce spontaneous and induced myo- metrial contractions. However, review of random- ized clinical trials, including four comparing magnesium sulfate with placebo/control or no ther- apy and 16 comparing magnesium sulfate with an alternate tocolytic regimen, has failed to demon- strate that magnesium sulfate is effective in prevent- ing preterm birth or reducing newborn morbidities or mortality as compared with alternative or no tocolytic treatments. Alternatively, -mimetics, cal- cium channel blockers, and cyclooxygenase inhib- itors were not found to be superior when compared with magnesium sulfate treatment. Recent meta- analyses and randomized controlled trials do not provide consistent evidence of a reduction in new- bornmorbidities or mortality with these other toco- lytic classes. Although it has been suggested that tocolytic therapy might improve short-term preg- nancy prolongation to facilitate antenatal cortico- steroid administration, we did not find improve- ments in delivery at 48 hours, respiratory distress syndrome, or intraventricular hemorrhage with magnesium sulfate, and we did not find any other tocolytic class to be superior to magnesium sulfate regarding these. It is disappointing that tocolytic treatment with magnesium sulfate and other agents has been so widely accepted in practice despite the 664 Mercer and Merlino Magnesium Sulfate for Preterm Labor OBSTETRICS & GYNECOLOGY relatively small number of patients studied and lack of evident benefits. Currently available data suggest that magnesium sulfate administration does not increase the risk of fetal and/or newborn mortality. Alternatively, accu- mulating evidence indicates that magnesium sulfate treatment before anticipated early preterm birth may be protective against long-term neurologic morbidi- ties including cerebral palsy. Because the potential benefits of antenatal magnesium sulfate were identi- fied only in secondary analyses from the recent major prospective trials, caution is warranted in incorporat- ing such treatment into clinical practice. The issues of tocolysis and neuroprotection should be treated as distinct entities. Magnesium sulfate should not be given as a tocolytic solely because it might offer neuroprotective benefits. Ultimately, it may be that magnesium sulfate neuroprotection may be most ef- fective for those who are not candidates for pregnancy prolongation as these are the pregnancies at highest risk for early delivery and newborn morbidities. Controlled trials and dose-response studies are needed to determine if magnesium sulfate tocolysis can result in significant improvements in perinatal out- comes. Similar studies are needed for the other classes of tocolytic agents. Future research regarding tocolytic therapies for preterm labor should include comparisons with a control group that is not treated, optimally a masked placebo regimen, and should be adequately powered to evaluate improvements in significant new- born morbidities and/or mortality, the primary reason for attempted pregnancy prolongation in the setting of preterm labor. Studies of magnesium sulfate tocolysis should include assessment of magnesium levels to iden- tify a clinically relevant therapeutic range, if any. Further research is needed to determine if tocolytic administra- tion concurrent with antenatal corticosteroid therapy, treatment of acute risk factors for preterm birth, or during maternal transport to a tertiary-care facility actu- ally improves outcomes related to these interventions. These studies may also help identify individuals who will respond differently to specific tocolytic regimens and those for whomattempts at pregnancy prolongation may be futile. In the meantime, practitioners should reconsider their current practices regarding tocolysis with magnesium sulfate and other classes of tocolytic agents. In light of the current evidence, the following treatment options are offered for consideration. Local practices, specific circumstances, and findings may alter the approach to any individual patient. 1. It is appropriate to withhold magnesium sulfate tocolysis from women presenting in preterm labor as neonatal benefit has not been demon- strated with such treatment. 2. If initiated to achieve time to accrue the benefits of antenatal corticosteroid administration, to facilitate patient transport, or during treatment of reversible causes of preterm labor, magne- sium sulfate treatment can be discontinued once these goals have been achieved or if labor subsides before then. 3. It is appropriate to withhold magnesium sulfate treatment from women with recurrent preterm labor after the above benefits have been ac- crued, as brief pregnancy prolongation is un- likely to improve neonatal outcomes once these goals have been achieved. 4. Because -mimetic, calcium channel blocker, and cyclooxygenase inhibitor therapies are not clearly superior to magnesium sulfate tocolysis, it is also appropriate to withhold tocolysis with these agents from women in presenting in pre- term labor. If used, discontinuation of treatment should be considered once the short-term ther- apeutic goal has been achieved. 5. Caregivers are encouraged to monitor for new information and guidelines regarding antenatal magnesium sulfate administration for neuropro- tection when early preterm birth is anticipated. 6. If magnesium sulfate is given for neuroprotec- tion, caregivers should follow a protocol used in one of the three major trials that have demon- strated benefits from this treatment. REFERENCES 1. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, et al. Births: final data for 2006. National vital statistics reports. Vol 57. Hyattsville, MD: National Center for Health Statistics; 2009. p.1104. 2. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001;107:E1. 3. Vohr BR, Wright LL, Poole WK, McDonald SA. Neurodevel- opmental outcomes of extremely low birth weight infants 32 weeks gestation between 1993 and 1998. Pediatrics 2005;116: 63543. 4. Hack M, Flannery DJ, Schluchter M, Cartar L, Borawski E, Klein N. Outcomes in young adulthood for very-low-birth- weight infants. N Engl J Med 2002;346:14957. 5. Hintz SR, Kendrick DE, Vohr BR, Poole WK, Higgins RD. National Institute of Child Health and Human Development Neonatal Research Network. Changes in neurodevelopmental outcomes at 18 to 22 months corrected age among infants of less than 25 weeks gestational age born in 1993-1999. Pediat- rics 2005;115:164551. VOL. 114, NO. 3, SEPTEMBER 2009 Mercer and Merlino Magnesium Sulfate for Preterm Labor 665 6. Meis PJ, Ernest JM, Moore ML. Causes of low birth weight births in public and private patients. Am J Obstet Gynecol 1987;156:11658. 7. Tucker JM, Goldenberg RL, Davis RO, Copper RL, Winkler CL, Hauth JC. Etiologies of preterm birth in an indigent population: is prevention a logical expectation? Obstet Gynecol 1991;77:3437. 8. Mercer BM, Goldenberg RL, Moawad AH, Meis PJ, Iams JD, Das AF, et al. The preterm prediction study: effect of gesta- tional age and cause of preterm birth on subsequent obstetric outcome. Am J Obstet Gynecol 1999;181:121621. 9. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD001060. DOI: 10.1002/14651858.CD001060. 10. Berkman ND, Thorp Jr, JM Hartmann KE, Lohr KN, Anjolie E, Idicula AE, et al. Management of preterm labor. Evidence Report/Technology Assessment No. 18. Research Triangle Institute. AHRQ Publication No. 01-E021. Rockville (MD): Agency for Healthcare Research and Quality; 2000. 11. Berkman ND, Thorp JM Jr, Lohr KN, Carey TS, Hartmann KE, Gavin NI, et al. Tocolytic treatment for the management of preterm labor: a review of the evidence. Am J Obstet Gynecol 2003;188:164859. 12. King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Data- base of Systematic Reviews 2005, Issue 2. Art. No.: CD001992. DOI: 10.1002/14651858.CD001992.pub2. 13. King JF, Flenady VJ, Papatsonis DNM, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labour. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD002255. DOI: 10.1002/14651858.CD002255. 14. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD004452. DOI: 10.1002/14651858.CD004452.pub2. 15. Duckitt K, Thornton S. Nitric oxide donors for the treatment of preterm labour. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD002860. DOI: 10.1002/ 14651858.CD002860. 16. Anotayanonth S, Subhedar NV, Neilson JP, Harigopal S. Betamimetics for inhibiting preterm labour. Cochrane Data- base of Systematic Reviews 2004, Issue 4. Art. No.: CD004352. DOI: 10.1002/14651858.CD004352.pub2. 17. Elin RJ. Magnesium: the fifth but forgotten electrolyte. Am J Clin Pathol 1994;102:61622. 18. Wolfe FI, Torsello A, Fasanella S, Cittadini A. Cell physiology of magnesium. Mol Aspects Med 2003;24:1126. 19. Standing committee on the scientific evaluation of dietary reference intakes, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorous, magnesium, vitamin D, and Fluoride. Washington, DC: National Academies Press; 1997. p. 190249. 20. Kurzel RB. Serum magnesium levels in pregnancy and pre- term labor. Am J Perinatol 1991;8:11927. 21. Weissberg N, Schwartz G, Shemesh O, Brooks BA, Algur N, Eylath U, et al. Serum and mononuclear cell potassium, magnesium, sodium and calcium in pregnancy and labour and their relation to uterine muscle contraction. Magnes Res 1992;5:1737. 22. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anesthes 1999;83:30220. 23. Quamme GA, Dirks JH. The physiology of renal magnesium handling. Ren Physiol 1986;9:25769. 24. Kumar D, Zourlas PA, Barnes AC. In vitro and in vivo effects of magnesium sulfate on human uterine contractility. Am J Obstet Gynecol 1963;86:103640. 25. Hall DG, Mcgaughey Jr, HS Corey EL, Thornton WN. The effects of magnesium therapy on the duration of labor. Am J Obstet Gynecol 1959;78:2732. 26. Fomin VP, Gibbs SG, Vanam R, Morimiya A, Hurd WW. Effect of magnesium sulfate on contractile force and intracel- lular calcium concentration in pregnant human myometrium. Am J Obstet Gynecol 2006;194:138490. 27. Phillippe M. Cellular mechanisms underlying magnesium sul- fate inhibition of phasic myometrial contractions. Biochem Biophys Res Commun 1998;252:5027. 28. Tica VI, Tica AA, Carlig V, Banica OS. Magnesium ion inhibits spontaneous and induced contractions of isolated uterine muscle. Gynecol Endocrinol 2007;23:36872. 29. Berger R, Garnier Y, Jensen A. Perinatal brain damage: underlying mechanisms and neuroprotective strategies. J Soc Gynecol Investig 2002;9:31928. 30. Hutchison HT, Nichols MM, Kuhn CR, Vasicka A. Effects of magnesium sulphate on uterine contractility, intrauterine fetus, and infant. Am J Obstet Gynecol 1964;88:74758. 31. Lyell DJ, Pullen K, Campbell L, Ching S, Druzin ML, Chitkara U, Burrs D, Caughey AB, El-Sayed YY. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor: a randomized controlled trial. Obstet Gynecol 2007;110:617. 32. Cotton DB, Strassner HT, Hill LM, Schifrin BS, Paul RH. Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. J Reprod Med 1984;29:927. 33. Cox SM, Sherman ML, Leveno KJ. Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol 1990;163:76772. 34. Fox MD, Allbert JR, McCaul JF, Martin RW, McLaughlin BN, Morrison JC. Neonatal morbidity between 34 and 37 weeks gestation. J Perinatol 1993;13:34953. 35. How HY, Zafaranchi L, Stella CL, Recht K, Maxwell RA, Sibai BM, et al. Tocolysis in women with preterm labor between 32 0/7 and 34 6/7 weeks of gestation: a randomized controlled pilot study. Am J Obstet Gynecol 2006;194:97681. 36. Miller JM, Keane MWD, Horger EO. Comparison of magne- sium sulfate and terbutaline for the arrest of premature labor. J Reprod Med 1982;27:34851. 37. Hollander DI, Nagey DA, Pupkin MJ. Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. Am J Obstet Gynecol 1987;156:6317. 38. Wilkins IA, Lynch L, Mehalek KE, Berkowitz GS, Berkowitz RL. Efficacy and side effects of magnesium sulfate and rito- drine as tocolytic agents. Am J Obstet Gynecol 1988;159: 6859. 39. Chau AC, Gabert HA, Miller JM. A prospective comparison of terbutaline and magnesium for tocolysis. Obstet Gynecol 1992;80:84751. 40. Floyd RC, McLauglin BN, Perry Jr, KG Martin RW, Sullivan CA, Morrison JC. Magnesium sulfate or nifedipine hydrochlo- ride for acute tocolysis of preterm labor: efficacy and side effects. J Matern Fetal Invest 1995;5:259. 41. Glock JL, Morales WJ. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: A randomized study. Am J Obstet Gynecol 1993;169:9604. 42. Haghighi L. Prevention of preterm delivery: nifedipine or magnesium sulfate. Int J Gynecol Obstet 1999;66:2978. 43. Larmon JE, Ross BS, May WL, Dickerson GA, Fischer RG, Morrison JC. Oral nicardipine versus intravenous magnesium 666 Mercer and Merlino Magnesium Sulfate for Preterm Labor OBSTETRICS & GYNECOLOGY sulfate for the treatment of preterm labor. Am J Obstet Gynecol 1999;181:14327. 44. Morales WJ, Madhav H. Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol 1993;169:97102. 45. Parilla BV, Tamura RK, Cohen LS, Clark E. Lack of effect of antenatal indomethacin on fetal cerebral blood flow. Am J Obstet Gynecol 1997;176:11669. 46. Schorr SJ, Ascarelli MH, Rust OA, Ross EL, Calfee EL, Perry KG, et al. A Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. South Med J 1998;91:102832. 47. McWhorter J, Carlan S, OLeary T, Richici K, OBrien W. Rofecoxib versus magnesium sulfate to arrest preterm labour: a randomized trial. Obstet Gynecol 2004;103:92330. 48. Borna S, Saeidi FM. Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. J Obstet Gynaecol Res 2007;33:6314. 49. Steer CM, Petrie RH. A comparison of magnesium sulfate and alcohol for the prevention of premature labor. Am J Obstet Gynecol 1977;129:14. 50. Aramayo FJ, Martinez FJ, Rosales CL. Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labor [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecol y Obstet de Mexico 1990;58:2659. 51. Armson BA, Samuels P, Miller F, Verbalis J, Main EK. Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. Am J Obstet Gynecol 1992;167:75865. 52. Beall MH, Edgar BW, Paul RM, Smith-Wallace T. A compar- ison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. Am J Obstet Gynecol 1985;153: 8549. 53. El-Sayed YY, Riley ET, Holbrook RH, Cohen SE, Chitkara U, Druzin ML. Randomized comparison of intravenous nitroglyc- erin and magnesium sulfate for treatment of preterm labor. Obstet Gynecol 1999;93:7983. 54. Ferguson JE, Hensleigh PA, Kredenster D. Adjunctive use of magnesium sulfate with ritodrine for preterm labour. Am J Obstet Gynecol 1984;148:16671. 55. Hatjis CG, Swain M, Nelson LH, Meis PJ, Ernest JM. Efficacy of combined administration of magnesium sulfate and rito- drine in the treatment of premature labor. Obstet Gynecol 1987;69:31722. 56. How HY, Cook CR, Cook VD, Miles DE, Spinnato JA. Preterm premature rupture of membranes: aggressive tocolysis versus expectant management. J Matern Fetal Med 1998;7: 812. 57. Ma L. Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei 1992;72:15861. 58. Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health out- comes in infants. Am J Obstet Gynecol 2002;186:11118. 59. Newton ER, Shields L, Ridgway LE, Berkus MD, Elliott BD. Combination antibiotics and indomethacin in idiopathic pre- term labor: a randomized double-blind clinical trial. Am J Obstet Gynecol 1991;165:17539. 60. Ogburn PL, Hansen CA, Williams PP, Butler JC, Joseph MS, Julian TM. Magnesium sulfate and B-mimetic dual-agent toco- lysis in preterm labor after single-agent failure. J Reprod Med 1985;30:5837. 61. Sciscione A, Gorman R, Schlossman P, Colmorgen G. A randomized prospective study of intravenous magnesium sul- fate, ritodrine, and subcutaneous terbutaline as treatments for preterm labor. Am J Obstet Gynecol 1993;168:376. 62. Tchilinguirian NG, Najem R, Sullivan GB, Craparo FJ. The use of ritodrine and magnesium sulfate in the arrest of prema- ture labor. Int J Gynaecol Obstet 1984;22:11723. 63. Weiner CP, Renk K, Klugman M. The therapeutic efficacy and cost-effectiveness of aggressive tocolysis for premature labor associated with premature rupture of the membranes. Am J Obstet Gynecol 1988;159:21622. 64. Wischnik A, Hettenbach A, Schmidt R, Zieger W, Hug G, Melchert F. The effect of magnesium sulfate on volume balance in tocolysis with the betamimetic agent fenoterol. Z Geburtshilfe Perinatol 1989;193:2515. 65. Zhu B, Fu Y. Treatment of preterm labor with ritodrine (translation). Chung Hua Fu Chan Ko Tsa Chih 1996;31: 7213. 66. Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part II double-blind study. J Perinat Med 1984;12:259. 67. Panter KR, Hannah ME, Amankwah KS, Ohlsson A, Jefferies AL, Farine D. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. Br J Obstet Gynaecol 1999;106:46773. 68. Papatsonis DN, Van Geijn HP, Ade` r HJ, Lange FM, Bleker OP, Dekker GA. Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstet Gynecol 1997;90:2304. 69. Rayamajhi R, Pratap K. A comparative study between nifedi- pine and isoxsuprine in the suppression of preterm labour. Kathmandu Univ Med J 2003;1:18590. 70. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95:2639. 71. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Dec- oufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth- weight children aged 3 to 5 years. JAMA 1996;276:180510. 72. Paneth N, Jetton J, Pinto-Martin J, Susser M. Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. The Neonatal Brain Hemor- rhage Study Analysis Group. Pediatrics 1997;99:E1. 73. Grether JK, Hoogstrate J, Walsh-Greene E, Nelson KB. Mag- nesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. Am J Obstet Gynecol 2000;183:71725. 74. Boyle CA, Yeargin-Allsopp M, Schendel DE, Holmgreen P, Oakley GP. Tocolytic magnesium sulfate exposure and risk of cerebral palsy among children with birth weights less than 1,750 grams. Am J Epidemiol 2000;152:1204. 75. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:187790. 76. Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sul- phate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG 2007;114:28999. 77. Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 1997;350: 15178. VOL. 114, NO. 3, SEPTEMBER 2009 Mercer and Merlino Magnesium Sulfate for Preterm Labor 667 78. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290: 266976. 79. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Le ve que Hellot MF, et al. Magnesium sulphate given before very- preterm birth to protect infant brain: the randomised con- trolled PREMAG trial. BJOG 2007;114:3108. 80. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magne- sium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359:895905. 81. Marret S, Marpeau L, Be nichou J. Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics 2008;121:2256. 82. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD004661. DOI: 10.1002/ 14651858.CD004661.pub3. 668 Mercer and Merlino Magnesium Sulfate for Preterm Labor OBSTETRICS & GYNECOLOGY